Latest News for: neurofibromatosis type i

Edit

Neurofibromatosis Type 1 Market Expected to Gain Momentum Through 2034, According to DelveInsight | AstraZeneca, ...

GetNews 13 Aug 2025
DelveInsight’s “Neurofibromatosis Type 1 Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Neurofibromatosis Type 1, historical ...
Edit

Neurofibromatosis Type 1 Pipeline Market Insights Report 2025 | Analysis of 10+ Companies and 12+ Drugs

Nasdaq Globe Newswire 28 Jul 2025
Discover the future of Neurofibromatosis Type 1 treatment with our "Pipeline Insight, 2025" report, featuring analysis of 10+ companies and 12+ drugs.
Edit

Neurofibromatosis Type 2 Market Set for Robust Growth Through 2034, Driven by Promising Pipeline Developments ...

GetNews 16 Jul 2025
Neurofibromatosis Type 2 pipeline insight provides comprehensive insights about the Neurofibromatosis Type 2 pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage ...
Edit

Neurofibromatosis Type 2 Market Set for Robust Growth Through 2034, Driven by Innovative Therapies and ...

GetNews 01 Jul 2025
Neurofibromatosis Type 2 pipeline insight provides comprehensive insights about the Neurofibromatosis Type 2 pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage ...
Edit

RI children get access to new therapy for neurofibromatosis type 1

The Jakarta Post 09 Jun 2025
ndonesian children with Neurofibromatosis Type 1 (NF1), a rare genetic condition where tumors grow on the nerves and skin, now have access to Selumetinib, the world’s first recognized therapy for NF1. .
Edit

Updated Data of Luvometinib (FCN-159) Treating Pediatric Patients with Neurofibromatosis Type 1 Announced at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Shanghai Fosun Pharmaceutical (Group) Co Ltd)

Public Technologies 06 Jun 2025
). The text version of this document is not available ... Attachments Original document Permalink.
Edit

Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven ...

Nasdaq Globe Newswire 15 May 2025
The neurofibromatosis type 1 market remains niche, but awareness campaigns, increased diagnoses, and treatment adoption, along with ongoing clinical trials, ...
  • 1

Article Search

tools
×
×
×
×